SGLT2i have moderate benefits on atherosclerotic major adverse cardiovascular events that seem confined to patients with established atherosclerotic cardiovascular disease. However, they have robust benefits on reducing hospitalisation for heart failure and progression of renal disease regardless of existing atherosclerotic cardiovascular disease or a history of heart failure (The Lancet)
Diabetes News
Glycosmedia is dedicated to bringing free, non-promotional, editorially independent news to a global audience about developments in diabetes, and is primarily aimed at health professionals.
The Physical Activity Guidelines for Americans
The Physical Activity Guidelines for Americans, 2nd edition, provides information and guidance on the types and amounts of physical activity that provide substantial health benefits (JAMA)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
In patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease, treatment with dapagliflozin did not result in a higher or lower rate of MACE than placebo but did result in a lower rate of cardiovascular death or hospitalization for heart failure, a finding that reflects a lower rate of hospitalization for heart failure (NEJM)
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
Among adults with type 2 diabetes and high CV and renal risk, linagliptin added to usual care compared with placebo added to usual care resulted in a noninferior risk of a composite CV outcome over a median 2.2 years (JAMA)
Prescribing for Diabetes in England – 2007/08 – 2017/18
Prescribing for Diabetes reports on and examines prescribing trends on medicines prescribed in primary care in England for the treatment and monitoring of diabetes during the period April 2007 to March 2018 (NHS Digital)
National Diabetes Audit Report 1 Care Processes and Treatment Targets 2017-18
A full report will be published in March 2019, which will contain full key findings, recommendations and results of initial analyses into cardiovascular risk reduction and the use of statins (NHS Digital)
Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes
Discontinuation of treatment with DPP-4 inhibitor should be considered for patients with diabetes when BP is diagnosed; the recently increased use of DPP-4 inhibitors may explain in part the increasing incidence of BP (JAMA Dermatology)
Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial)
Renal biomarkers informing various aspects of kidney function may further our understanding of the complex interplay between diabetic kidney disease and cardiovascular disease (American Journal of Cardiology)
Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial
ASP8232 is effective in reducing albuminuria in patients with diabetic kidney disease and is safe and well tolerated. These findings warrant further research to ascertain the effect of ASP8232 on delaying progression of diabetic kidney disease (The Lancet Diabetes & Endocrinology)
Ascorbic acid supplementation improves postprandial glycaemic control and blood pressure in people with type 2 diabetes: Findings of a randomized cross‐over trial
People with type 2 diabetes experienced improved postprandial and 24 h glycaemia and decreased blood pressure after 4 months of AA supplementation when compared to placebo. These findings offer evidence for the proposed use of AA as an adjunct therapy to improve glycaemic and blood pressure control in people with type 2 diabetes (Diabetes, Obesity and Metabolism)
Double‐blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase‐4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT‐I Study
When initiating insulin glargine therapy, continuation of sitagliptin, compared with discontinuation, resulted in a clinically meaningful greater reduction in HbA1c without an increase in hypoglycemia (Diabetes, Obesity and Metabolism)
Efficacy of a self-management education programme on patients with type 2 diabetes in primary care: A randomised controlled trial
HbA1c reductions are difficult to obtain in adequately controlled patients. On the other hand, raising awareness on one´s disease can increase disease control self-efficacy. This finding, accompanied by reduced medication consumption and healthcare use rates, highlights that usual care would be benefited by incorporating certain SDSMP aspects (Primary Care Diabetes)
Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial
Lixisenatide reduces progression of UACR in macroalbuminuric patients, and is associated with a lower risk of new-onset macroalbuminuria after adjustment for baseline and on-trial HbA 1c and other traditional renal risk factors (The Lancet Diabetes & Endocrinology)
Comparative efficacy of individual renin–angiotensin system inhibitors on major renal outcomes in diabetic kidney disease: a network meta-analysis
Based on the available evidence, individual ACEIs and ARBs at goal doses appeared to have no or little differences in their effect on major renal outcomes (Nephrology Dialysis Transplantation)
Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease
Evidence concerning the efficacy and safety of glucose‐lowering agents for people with diabetes and CKD is limited. SGLT2 inhibitors and GLP‐1 agonists are probably efficacious for lowering glucose levels. Other potential effects of SGLT2 inhibitors include lower BP, lower potassium levels and a reduced risk of heart failure but an increased risk of genital infections. The safety of GLP‐1 agonists is uncertain (Cochrane Library)
The association between diabetes mellitus and reduction in myocardial glucose uptake: a population-based 18F-FDG PET/CT study
Diabetes is associated with decreased myocardial glucose metabolism, which is mediated by multiple metabolic abnormalities (BMC Cardiovascular Disorders)
Glycemic control with a basal-bolus insulin protocol in hospitalized diabetic patients treated with glucocorticoids: a retrospective cohort study
A significantly higher percentage of patients with diabetes who were treated with glucocorticoids during hospitalization did not achieve glycemic control with a basal-bolus insulin protocol (BMC Endocrine Disorders)
Creatinine Rise During Blood Pressure Therapy and the Risk of Adverse Clinical Outcomes in Patients With Type 2 Diabetes Mellitus
These data suggest that a >30% serum creatinine increase that coincides with lower blood pressure values should not directly lead to a reduction in antihypertensive medication in patients with type 2 diabetes mellitus (Hypertension)
Diabetes, Plasma Glucose, and Incidence of Fatty Liver, Cirrhosis, and Liver Cancer: A Prospective Study of 0.5 Million People
In Chinese adults, diabetes and higher blood glucose levels among those without known diabetes are associated with higher risks of liver cancer and major chronic liver diseases (Hepatology)
Evaluation of the Long‐Term Cost‐Effectiveness of Once‐Weekly semaglutide versus dulaglutide for the treatment of type 2 diabetes mellitus in the UK
Compared with treatment with dulaglutide, once‐weekly semaglutide represents a cost‐effective option for treating people with T2DM not achieving glycaemic control on metformin in the UK, projected to both improve clinical outcomes and reduce costs (Diabetes, Obesity and Metabolism)
- 1
- 2
- 3
- …
- 169
- Next Page »
Glycosmedia is also available as an App: